Tools & Technology

The latest news on life science tools and technology in genetics, genomics, and molecular diagnostics.

The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.

The test measures the multiple myeloma marker M protein and could prove more sensitive and less susceptible to interferences than existing assays.

They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.

OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.

The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.